(19)
(11) EP 1 682 177 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.09.2010 Bulletin 2010/35

(45) Mention of the grant of the patent:
21.07.2010 Bulletin 2010/29

(21) Application number: 04810417.8

(22) Date of filing: 04.11.2004
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
(86) International application number:
PCT/US2004/036954
(87) International publication number:
WO 2005/044304 (19.05.2005 Gazette 2005/20)

(54)

USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

VERWENDUNG VON ANTAGONISTEN-ANTI-CD40-ANTIKÖRPERN ZUR BEHANDLUNG VON CHRONISCH LYMPHOZYTISCHER LEUKÄMIE

UTILISATION D'ANTICORPS ANTI-CD40 ANTAGONISTES POUR LE TRAITEMENT DE LA LEUCEMIE LYMPHOCYTIQUE CHRONIQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 04.11.2003 US 517337 P
26.11.2003 US 525579 P
27.04.2004 US 565710 P
21.09.2004 US 611794 P

(43) Date of publication of application:
26.07.2006 Bulletin 2006/30

(60) Divisional application:
10007491.3

(73) Proprietors:
  • Novartis Vaccines and Diagnostics, Inc.
    Emeryville, CA 94608 (US)
  • XOMA Technology Ltd.
    Hamilton HM11 (BM)

(72) Inventors:
  • LONG, Li
    Emeryville, CA 94662-8097 (US)
  • LUQMAN, Mohammad
    Emeryville, CA 94662-8097 (US)
  • YABANNAVAR, Asha
    Emeryville, CA 94662-8097 (US)
  • ZAROR, Isabel
    Emeryville, CA 94662-8097 (US)
  • AUKERMAN, Sharon, Lea
    Emeryville, CA 94662-8097 (US)

(74) Representative: Marshall, Cameron John et al
Carpmaels & Ransford One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
WO-A-01/83755
WO-A-02/28904
 WO-A-02/28480
WO-A-02/088186
   
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2002 (2002-08), ELLMARK PETER ET AL: "Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library" XP002326955 Database accession no. PREV200200495981 & IMMUNOLOGY, vol. 106, no. 4, August 2002 (2002-08), pages 456-463, ISSN: 0019-2805
  • DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), WENG WEN-KAI ET AL: "Human anti-CD40 antagonistic antibodies inhibit the proliferation of human B cell non-Hodgkin's lymphoma" XP002326956 Database accession no. PREV200200241215 & BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), page 466a, 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 1; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001 ISSN: 0006-4971
  • BALINT ROBERT., LARRICK JAMES: "Antibody engineering by parsimonious mutagenesis" GENE, vol. 137, 27 December 1993 (1993-12-27), pages 109-118,
  • LITTLE M. ET AL.: "Of mice and men: hybridoma and recombinant antibodies" REVIEW IMMUNOLOGY TODAY, vol. 21, August 2000 (2000-08), pages 364-370,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).